These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38487532)

  • 1. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
    Deng W; Chen J; Deng XY
    Front Immunol; 2024; 15():1333850. PubMed ID: 38487532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
    Ying X; Shi Z; Shao R; You G; Song Z
    Neoplasma; 2024 Jun; 71(3):297-305. PubMed ID: 38958712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
    Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
    Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.
    Jiang Y; Zhang L; Zhu F; Zhu H; Cao X; Zhang Y
    Ann Palliat Med; 2022 Mar; 11(3):1135-1146. PubMed ID: 35365044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
    Yu L; Xu J; Qiao R; Han B; Zhong H; Zhong R
    Cancer Med; 2023 Mar; 12(5):5372-5383. PubMed ID: 36250532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study.
    Yang P; Luo H; Zhao L; Xiong F; Tang C
    J Thorac Dis; 2024 Jul; 16(7):4391-4399. PubMed ID: 39144292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
    Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
    Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
    Wu G; Huang J; Lin L; Yan S; Pan W; Chen Q; Wu X; Lv D
    Immunotherapy; 2022 Sep; 14(13):1007-1013. PubMed ID: 35852100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
    Wu Y; Zhang T; Liu Y; Wang J; Bi N
    Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
    Yu G; Cai Q; Xu X; Shen Y; Xu K
    PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.
    Han X; Guo J; Li L; Huang Y; Meng X; Wang L; Zhu H; Meng X; Shao Q; Li X; Zhang Y; Wang J; Chen Y; Zhang Y; Chen Y; Zhu C; Wang Z
    Signal Transduct Target Ther; 2024 Sep; 9(1):241. PubMed ID: 39278918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.
    Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
    Front Oncol; 2022; 12():846597. PubMed ID: 35321433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.